Treatment patterns and survival in metastatic castration-sensitive prostate cancer in the US Veterans Health Administration.

ABSTRACT:

Background

Limited real-world data exist on treatment patterns and outcomes in patients with metastatic castration-sensitive prostate cancer (mCSPC).

Methods

A retrospective cohort study was conducted, using the Veterans Health Administration claims database (April 2013-March 2018). Among 369,734 prostate cancer patients, we selected all men who developed metastases within 90 days before or after medical/surgical castration and who received androgen deprivation therapy (ADT). Patients were categorized into four cohorts: ADT-only (± <90-day nonsteroidal anti-androgen [NSAA] use), ADT + NSAA, ADT + docetaxel, and ADT + abiraterone. Main outcomes were treatment patterns, time-to-progression to metastatic castration-resistant disease, and overall survival. Multivariable analysis

SUBMITTER: Freedland SJ 

PROVIDER: S-EPMC8633245 | biostudies-literature | 2021 Dec

REPOSITORIES: biostudies-literature